Remove 2019 Remove Marketing Remove Therapy
article thumbnail

Wellness Marketing: The Future Of Marketing For Wellness Industry

American Esthetician Organization

Are you looking to learn more about the latest trends in wellness marketing? This post explores everything you need to know about wellness marketing and how companies are leveraging consumer interest in improving overall well-being. Wellness industry is projected to reach $7 trillion by 2025.

article thumbnail

Proven Skincare Marketing Ideas That Will Boost Your Online Sales

American Esthetician Organization

Introducing skincare marketing ideas that can be daunting, especially when it comes to boosting online sales. According to a Research, beauty product sales accounted for $432 billion globally in 2019 and are expected to increase significantly over the next few years.

Sales 88
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Does NAD+ IV “Drip” Therapy Work?

Aesthetics Advisor

Key Points: A few studies show that NAD+ IV therapy can alleviate alcohol and drug addiction, as well as Parkinson’s disease, but no studies have examined its effects on aging. Oral administration of NAD+ boosting therapy is safer, more cost effective, and more consistently dosed than intravenous administartion.

Therapy 36
article thumbnail

FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD

The Dermatology Digest

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.

article thumbnail

FDA Approves Galderma’s IL-31 Blocker in PN

The Dermatology Digest

Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. FDA has also accepted for review the Biologics License Application for nemolizumab for the treatment of moderate-to-severe atopic dermatitis, with a decision anticipated later this year.

article thumbnail

GWI’s Susie Ellis talks 2024, trends & the global wellness economy

Spa Executive

Global Wellness Institute CEO, Susie Ellis, talks about 2024, trends, and the growing wellness market. Ellis introduced the industry’s first Global Wellness Trends Report in 2004 and the first Global Wellness Economy Monitor in 2014, the first research that provided global market data for every sector of the wellness economy.

article thumbnail

Nemolizumab Update: Galderma’s IL-31 Blocker Continues to Wow in PN, AD

The Dermatology Digest

In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. The FDA has granted nemolizumab Priority Review for prurigo nodularis.